Video Center

The Invasive Breast Cancer Video Center features educational videos providing information about the Oncotype DX® Breast Recurrence Score™. Use the tabs below to jump directly to your topic of interest.

TAILORx - An Interview with Dr. Joe Sparano, Lead Investigator

Published in the New England Journal of Medicine, the watershed TAILORx trial finds 99 percent of women with an Oncotype DX Breast Recurrence Score of 10 or less are free of breast cancer recurrence after five years of hormone therapy alone. TAILORx, which enrolled more than 10,000 patients at nearly 1,200 sites in six countries, is the largest adjuvant breast cancer trial and the first prospectively conducted clinical trial in which patients were uniformly treated based on a genomic test. “The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice,” said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women’s health at Albert Einstein College of Medicine.

Impact of the Oncotype DX Breast Recurrence Score Over the Past Ten Years

Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Lee Schwartzberg, Chief, Division of Hematology Oncology and Professor of Medicine at the University of Tennessee Health Science Center, discuss Genomic Health's Oncotype DX
Breast Recurrence Score and how it has impacted breast cancer treatment decisions over the past ten years.

Genomic Testing Options for ER+ Breast Cancers

Estrogen receptor positive (ER+) breast cancer and its treatment options with genomic testing are analyzed by Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. David Hyams, Medical Director, Desert Surgical Oncology at the Eisenhower Medical Center.

Discussing the Breast Recurrence Score Results with Patients

Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California, San Francisco, talk about discussing the Breast Recurrence Score results with their breast cancer patients.

Genomic Testing Guidelines and Multidisciplinary Breast Cancer Treatment Decisions

Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City discusses standardized breast cancer treatment and how the evolving genomic testing guidelines can help expedite treatment decisions to reduce patient anxiety and make it easier understand the course of treatment they face.

Using the Oncotype DX Breast Recurrence Score with the Treatment of Micrometastatic Disease

Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Kathy Albain of the Loyola University Medical Center talk about treating micrometastatic breast cancer with the Oncotype DX Breast Recurrence Score.

Breast Cancer Tumor Biology: An Advantage for Surgeons

Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City, discusses the evolution and technology of multi-gene tests, like the Oncotype DX Breast Recurrence Score, and how they help surgeons discuss the biology of breast cancer tumors with their patients and how that plays a role in their care and individualized treatment decisions. Dr. Shook refers to an publication in The American Journal of Surgery "The Role of the Breast Cancer Surgeon in Personalized Cancer Care: Clinical Utility of the 21-Gene Assay," by Christine Laronga, MD, FACS with the Moffitt Cancer Center in Tampa, Florida.

The Oncotype DX Breast Recurrence Score and Neoadjuvant Therapy Decisions

Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City, talks about how the Oncotype DX Breast Recurrence Score can determine whether neoadjuvant therapy for breast cancer patients is more beneficial than radical procedures, like a mastectomy or lumpectomy.

Next: Newsletter